Bronchiectasis

Etiology, Pathophysiology, Diagnosis, and Management

1. Introduction
Bronchiectasis is a chronic, progressive respiratory disease where the bronchi and bronchioles
become permanently and abnormally enlarged. This dilation occurs due to damage to the
elastic and muscular parts of the bronchial wall, often from repeated cycles of infection and
inflammation. Unlike acute bronchitis, the structural damage in bronchiectasis is permanent.
The main feature of the disease is impaired mucociliary clearance, which leads to mucus
buildup in the damaged, dilated airways. This stagnant mucus creates an ideal environment for
bacteria to grow, resulting in frequent chest infections, a chronic cough, and a steady decline in
lung function. Bronchiectasis can either occur as a primary condition or, more commonly, as a
secondary issue related to another underlying problem like cystic fibrosis, severe childhood
pneumonia, tuberculosis, or immune deficiency.
Previously seen as a rare lung disease, better imaging techniques, particularly high-resolution
CT, have revealed that bronchiectasis is more common than once believed. It remains a
significant cause of chronic respiratory issues around the world.

2. Causes (Etiology)
Bronchiectasis is not a single disease; instead, it represents the end result of various factors
that damage the airway. The causes are generally categorized as follows:

2.1 Post-infectious causes

• Severe bacterial pneumonia, especially in childhood
• Viral infections such as measles, adenovirus, or whooping cough
• Pulmonary tuberculosis
• Fungal infections like allergic bronchopulmonary aspergillosis (ABPA)

2.2 Congenital and genetic causes

• Cystic fibrosis, the most common genetic cause
• Primary ciliary dyskinesia, including Kartagener syndrome
• Alpha-1 antitrypsin deficiency

2.3 Immunodeficiency states

• Primary immunodeficiencies, e.g., common variable immunodeficiency
• Secondary immunodeficiency, e.g., HIV infection or immunosuppressive therapy

1
2.4 Airway obstruction
• Inhaled foreign body, especially in children
• Endobronchial tumors
• Enlarged lymph nodes compressing a bronchus
• Mucus plugging

2.5 Aspiration and reflux

• Gastroesophageal reflux disease (GERD) leading to chronic aspiration
• Impaired swallowing

2.6 Autoimmune and inflammatory conditions

• Rheumatoid arthritis
• Inflammatory bowel disease
• Connective tissue disorders

2.7 Idiopathic
In many patients, despite comprehensive testing, no clear cause for the condition can be found;
these cases are labeled idiopathic bronchiectasis.

3. Pathophysiology – How It Affects the Body

The pathophysiology of bronchiectasis is best described by Cole's “vicious cycle” hypothesis,
which illustrates a self-reinforcing pattern of airway damage:
1. Initial insult: An infection, blockage, or genetic issue harms the bronchial lining and
disrupts the normal mucociliary function.
2. Mucus buildup: With cilia unable to clear mucus effectively, it accumulates in the airway.
3. Bacterial growth: Stagnant mucus becomes a breeding ground for bacteria like
Haemophilus influenzae, Pseudomonas aeruginosa, and Staphylococcus aureus.
4. Chronic inflammation: Ongoing infection prompts a strong immune response, with
neutrophils releasing enzymes, reactive oxygen species, and pro-inflammatory
substances.
5. Structural damage: These inflammatory agents gradually destroy the elastin, smooth
muscle, and cartilage of the bronchial wall, leading to irreversible dilation, scarring, and
loss of normal structure.
6. Worsening clearance: The damaged, widened airway struggles even more to clear mucus
and bacteria, continuing the cycle and fueling further infection and inflammation.
Over time, this cycle causes several notable changes in the lungs:

2
 • The bronchial walls become thickened, fragile, and overly vascular, making them prone to
bleeding.
• Mucus blockage and airway collapse result in regional airflow obstruction and ventilation–
perfusion mismatch, impairing gas exchange efficiency.
• Surrounding lung tissue may develop fibrosis due to chronic inflammation.
• In advanced cases, decreasing lung function may lead to chronic respiratory failure,
pulmonary hypertension, and right-sided heart strain.
Essentially, bronchiectasis transforms the airway from a self-cleaning structure into a
chronically infected, severely damaged pathway that leads to ongoing lung injury.

4. Signs and Symptoms

• Persistent cough lasting weeks to years, often productive.
• Sputum is usually abundant, purulent, and worse in the morning.
• Recurrent chest infections, occurring several times a year in many patients.
• Hemoptysis, which can range from blood-streaked sputum to, rarely, significant bleeding,
due to fragile airway walls.
• Shortness of breath during activity, worsening over time.
• Wheezing and tightness in the chest for some patients.
• Fatigue and malaise, especially during flare-ups.
• Weight loss and decreased appetite in severe or long-standing cases.
• Occasionally, pleuritic chest pain.
• Digital clubbing of the fingers in some patients with severe disease.
• Coarse crackles, rhonchi, or wheezing during a chest exam.

5. Diagnosis
Diagnosis involves combining clinical suspicion with imaging, microbiology, and investigations
for any underlying causes.

5.1 Imaging
High-resolution computed tomography (HRCT) of the chest is the gold-standard test and is very
sensitive. Characteristic findings include the “signet ring sign” (a dilated bronchus that appears
larger than its corresponding pulmonary artery), “tram-track” parallel airway walls, thickened
bronchial walls, and missing normal airway tapering.
Chest X-ray can show increased lung markings or cystic changes but is less sensitive than HRCT.
It may appear normal in mild cases.

3
5.2 Microbiology
Sputum culture and sensitivity testing during stable periods and flare-ups help identify bacteria
causing infection (often Haemophilus influenzae, Pseudomonas aeruginosa, Staphylococcus
aureus) and guide antibiotic choices.

5.3 Pulmonary function tests

Spirometry typically shows an obstructive pattern (a reduced FEV1/FVC ratio), while a mixed or
restrictive pattern can appear in more advanced cases.

5.4 Investigations for underlying causes

• Sweat chloride test or genetic testing for cystic fibrosis.
• Serum immunoglobulin levels to check for immunodeficiency.
• Ciliary studies or nasal nitric oxide tests for primary ciliary dyskinesia.
• Autoimmune markers (like rheumatoid factor, ANA) if connective tissue disease is
suspected.
• Aspergillus-specific IgE and IgG, total IgE if ABPA is suspected.

5.5 Bronchoscopy
Used selectively, particularly to check for a localized obstructing lesion (like a foreign body or
tumor) or to obtain samples for microbiology.

6. Treatment and Management

Management focuses on breaking the cycle of infection and inflammation, improving mucus
clearance, controlling symptoms, treating any identifiable causes, and preserving long-term
lung function.

6.1 Airway clearance

• Chest physiotherapy and postural drainage to help clear secretions.
• Airway clearance devices, like oscillating positive expiratory pressure (PEP) devices (for
example, flutter or acapella devices).
• Regular exercise and pulmonary rehabilitation to improve overall respiratory fitness.

6.2 Pharmacological therapy

• Nebulized hypertonic saline or other mucolytics to thin secretions and assist in clearance.
• Targeted treatments, ideally guided by sputum culture, to address acute symptom
worsening.
• Antibiotics for flare-ups are often needed in patients with frequent exacerbations;
macrolides like azithromycin are frequently chosen for their additional anti-inflammatory
effects.

4
 • Long-term or preventive antibiotics may also be necessary.
• Inhaled beta-agonists or anticholinergics for patients with airflow obstruction or wheeze.
• Inhaled corticosteroids may be considered for some patients, especially if there's
overlapping asthma or significant airway inflammation.
• Treating any identified underlying cause, such as immunoglobulin replacement for
immunodeficiency or corticosteroids and antifungals for ABPA.

6.3 Vaccination and prevention

• Annual flu shots and pneumococcal vaccines to lower the risk of triggering infections.
• Cessation of smoking and steering clear of air pollutants.

6.4 Surgical and advanced options

• Surgery may be an option for localized, severe disease in one lobe or segment that has not
responded to medical therapy.
• Bronchial artery embolization for significant or recurrent hemoptysis.
• Lung transplantation is reserved for cases of end-stage disease with severe, progressive
respiratory failure.

6.5 Supportive care

• Nutritional support, because chronic infection and the increase in breathing effort can
lead to weight loss.
• Educating patients on recognizing early signs of exacerbation and sticking to daily airway
clearance routines, as these are crucial for long-term outcomes.

7. Conclusion
Bronchiectasis is a chronic, often progressive lung disease driven by a repeating cycle of
infection, inflammation, and permanent airway damage. It can arise from various causes,
including childhood illnesses, genetic issues, immune deficiencies, and airway blockages,
though many cases remain idiopathic. Its main features — chronic productive cough, recurrent
infections, and increasing shortness of breath — greatly affect quality of life and can lead to
respiratory failure in advanced stages.
Early detection through high-resolution CT, coupled with a thorough search for an underlying
cause, allows healthcare providers to customize treatment. While the structural damage of
bronchiectasis cannot be undone, a well-rounded approach that includes airway clearance
techniques, targeted antibiotic treatment, addressing underlying conditions, vaccination, and
patient education can significantly slow disease progression, reduce the frequency of flare-ups,
and enhance overall quality of life. A team-based, patient-focused method is essential for
achieving the best long-term results.

5
References
Broaddus, V. C., Ernst, J. D., King, T. E., Jr., Lazarus, S. C., Sarmiento, K. F., Schnapp, L. M.,
Stapleton, R. D., & Gotway, M. B. (Eds.). (2022). Murray and Nadel’s textbook of
respiratory medicine (7th ed.). Elsevier. [Link]
nadels-textbook-of-respiratory-medicine-2-volume-set/broaddus/978-0-323-65587-3
Brunton, L. L., & Knollmann, B. C. (Eds.). (2022). Goodman & Gilman’s the pharmacological
basis of therapeutics (14th ed.). McGraw Hill.
[Link]
[Link]
Hill, A. T., Sullivan, A. L., Chalmers, J. D., De Soyza, A., Elborn, S. J., Floto, R. A., Grillo, L.,
Gruffydd-Jones, K., Harvey, A., Haworth, C. S., Hiscocks, E., Hurst, J. R., Johnson, C.,
Kelleher, W. P., Bedi, P., Payne, K., Saleh, H., Screaton, N. J., Smith, M., … Loebinger, M.
R. (2019). British Thoracic Society guideline for bronchiectasis in adults. Thorax,
74(Suppl 1), 1–69. [Link]
Loscalzo, J., Fauci, A., Kasper, D., Hauser, S., Longo, D., & Jameson, J. L. (Eds.). (2022). Harrison’s
principles of internal medicine (21st ed.). McGraw Hill.
[Link]